Supreme Court Preserves Access to Abortion Pill Mifepristone Amid Ongoing Lawsuit
The US Supreme Court has issued an order preserving nationwide access to mifepristone, a widely used abortion medication, while legal challenges proceed. The decision rejects lower-court restrictions that would have halted mail delivery and required in-person doctor visits, effectively maintaining the status quo established by the FDA five years ago. This emergency stay grants relief to manufacturers Danco Laboratories and GenBioPro, ensuring uninterrupted access via pharmacies and mail at least until next year. Justices Clarence Thomas and Samuel Alito dissented, arguing that the companies profit from what they termed a criminal enterprise violating the Comstock Act and state laws. The case originates from a lawsuit by Louisiana, which contends that federal prescribing rules undermine its state abortion ban and question drug safety, despite FDA affirmations. The ruling occurs within a charged political environment under President Donald Trump’s administration, where anti-abortion groups are pressuring the FDA for stricter regulations. This development follows the recent resignation of FDA Commissioner Marty Makary amid criticism from Trump allies. The court's action highlights the continuing legal and political friction surrounding abortion access four years after the overturning of Roe v. Wade.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection